Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Profit After Tax (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Profit After Tax for 14 consecutive years, with -$113719.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 231.04% year-over-year to -$113719.0, compared with a TTM value of -$393343.0 through Nov 2025, up 28.62%, and an annual FY2025 reading of -$313976.0, up 54.84% over the prior year.
  • Profit After Tax was -$113719.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$150109.0 in the prior quarter.
  • Across five years, Profit After Tax topped out at -$34352.0 in Q4 2024 and bottomed at -$2.6 million in Q1 2023.
  • Average Profit After Tax over 5 years is -$554802.8, with a median of -$341564.0 recorded in 2022.
  • The sharpest move saw Profit After Tax surged 89.44% in 2024, then crashed 231.04% in 2025.
  • Year by year, Profit After Tax stood at -$1.3 million in 2021, then surged by 72.97% to -$357669.0 in 2022, then skyrocketed by 50.09% to -$178523.0 in 2023, then soared by 80.76% to -$34352.0 in 2024, then plummeted by 231.04% to -$113719.0 in 2025.
  • Business Quant data shows Profit After Tax for CNBX at -$113719.0 in Q4 2025, -$150109.0 in Q3 2025, and -$59727.0 in Q2 2025.